Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback